Clinical Trial

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-15; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-08-13
Trial Details
NCT Number NCT06940518
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Strategic Alliance, Summit Therapeutics
Conditions Ivonescimab, Clear Cell Renal Carcinoma
Enrollment 40 participants
Start Date 2025-07-02
Primary Completion 2028-01-19 (estimated)
Study Completion 2030-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-12